|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | All (N = 99) | IO-IO (n = 65) | IO-TKI (n = 34) | *p*-Value |
| Follow-up duration, months, median (IQR) | | 19.0 (6.9–32.5) | 22.4 (8.4–36.8) | 10.2 (6.3–25.0) | 0.030 |
| Age, years, median (IQR) | | 69 (63–74) | 67 (61–73) | 71 (66–75) | 0.090 |
| Sex, n (%) | |  |  |  | 0.050 |
|  | Male | 78 (78.8) | 55 (84.6) | 23 (67.7) |  |
|  | Female | 21 (21.2) | 10 (15.4) | 11 (32.3) |  |
| IMDC, n (%) | |  |  |  | 0.060 |
|  | Intermediate | 63 (63.6) | 37 (56.9) | 26 (76.5) |  |
|  | Poor | 36 (36.4) | 28 (43.1) | 8 (23.5) |  |
| Subtype, n (%) | |  |  |  | 0.650 |
|  | Clear | 79 (79.8) | 51 (78.5) | 28 (82.4) |  |
|  | Non-clear/not confirmed | 20 (20.2) | 14 (21.5) | 6 (17.6) |  |
| 1st-line treatment, n (%) | |  |  |  |  |
|  | Nivolumab + Ipilimumab | 65 (65.7) | 65 (100) | 0 |  |
|  | Avelumab + Axitinib | 5 (5.1) | 0 | 5 (14.7) |  |
|  | Pembrolizumab + Axitinib | 10 (10.1) | 0 | 10 (29.4) |  |
|  | Nivolumab + Cabozantinib | 5 (5.1) | 0 | 5 (14.7) |  |
|  | Pembrolizumab + Lenvatinib | 14 (14.1) | 0 | 14 (41.2) |  |
| Prior Nephrectomy, n (%) | |  |  |  | 0.080 |
|  | Yes | 52 (52.5) | 30 (46.2) | 22 (64.7) |  |
|  | No | 47 (47.5) | 35 (53.8) | 12 (35.3) |  |
| Number of metastatic organs, n (%) | |  |  |  | 0.450 |
|  | 1 | 56 (56.6) | 35 (53.9) | 21 (61.8) |  |
|  | 2 | 43 (43.4) | 30 (46.2) | 13 (38.2) |  |
| Metastatic organ sites at baseline | |  |  |  |  |
|  | Lung | 56 (56.6) | 34 (52.3) | 22 (64.7) | 0.230 |
|  | Liver | 9 (9.1) | 8 (12.3) | 1 (2.9) | 0.120 |
|  | Lymph node | 23 (23.2) | 14 (21.5) | 9 (26.5) | 0.580 |
|  | Bone | 24 (24.2) | 18 (27.7) | 6 (17.7) | 0.270 |
|  | Brain | 5 (5.1) | 3 (4.6) | 2 (5.9) | 0.780 |
|  | Pancreas | 6 (6.1) | 4 (6.2) | 2 (5.9) | 0.960 |
|  | Others | 19 (19.2) | 14 (21.5) | 5 (14.7) | 0.410 |

Supplementary Table II. Patient characteristics (less than three metastatic organs).

Abbreviations: N, number; IO, immune-oncologic drug; TKI, tyrosine kinase inhibitor; IQR, interquartile range; IMDC, international metastatic renal cell carcinoma database consortium